In GBM where angiogenesis is thought to be the hallmark of pathogenesis and VEGF its main driver (215), combining VEGF/EGFR with RT has been shown to halt the growth of glioma cells preclinically (216) and to have a significant synergistic anti-tumor effect with RT (217, 218). The gene discussed is EGFR; the disease is neoplasm.